A patient view on the ABPI’s patient collaboration sourcebook
July 25, 2019 | ABPI, Patient-centric, patient, patient advocate, patient collaboration, sourcebook
Last month, the ABPI released a much-in-demand document: The Working with Patients and Patient Organisations sourcebook.
Last month, the ABPI released a much-in-demand document: The Working with Patients and Patient Organisations sourcebook. It is a soothing balm for those organisations in 2019, who whether through accident or fear, remain patient-shy. It sets out a thorough and accessible foundation for collaborations between patient advocates and pharmaceutical organisations.
A balm, and perhaps a nail in the coffin for organisations who refuse to work with patients. But then I would say that; I’m a patient. The common culprits cited against collaboration are dispatched with ease: ‘we don’t have the know-how to interact with patients’, ‘the ABPI code isn’t clear on what’s allowed’, ‘we don’t know how to define patient collaboration’.
A sympathetic ally
On these points the sourcebook is a strong ally, the latter in particular. It’s most helpful at detailing the types of patient interaction, types of patients drawn to those interactions and why such interactions are valuable.
From a patient perspective it’s also reassuring. For those new to advocacy work or industry involvement, it’s an invaluable blueprint on what to expect from a project. When it comes to practical concerns like travel reimbursement and accommodating carers this is crucial. If at any time the reality falls short of expectations, there is now a guide spelled out by a respected and influential industry voice that can serve as a back-up.
The sourcebook is broken down into five areas: principles and agreements, definitions, events and meetings, research and development, product launches and payment. At times, it is impressively astute. In ‘definitions’, it’s quick to remind that when identifying or labelling patient collaborators, assumptions must be avoided. How and why people want to be known is important. Case in point, I have spoken at industry events several times. Despite any relevant skills and motivations for being at that event, I have almost always been introduced as a patient before anything else, and usually without being asked. I don’t mind the patient moniker, I’ve had a lifetime to get used to it! But, like many, I object to being seen as ‘only’ or ‘just’ a patient. The term ‘patient’ is so heavy and full of connotation, it’s hard for even the most self-assured person not to get lost under it.
The experiential vs academic breakdown of patient knowledge (pg 10) is a highlight. While other organisations have classified patients working in industry, the depth here is unusual. This categorisation can be used to inform the nature, responsibilities and subsequently, any compensation, of a patient’s role across many different project types.
One point on compensation; this section could go further. The surrender of personal, in-demand data, should always be compensated. That remains true in every context, but in health the stakes are higher. There are reasons why some people choose not to accept compensation, but that should never pre-empt the decision not to offer. Staying empowered as a patient is key, sometimes that’s achieved through patient education or respecting personal preferences, sometimes it’s about feeling our experience and time is valued too.
Advisory boards (ABs) are also given some much needed scrutiny. It’s encouraging that ABs are becoming commonplace, but they are at risk of looking like a tick-box exercise and should never be seen as a guaranteed path to meaningful patient engagement. But if pharma and agencies use the checklist on when and why to employ them (pg 14), they can take a moment to consider when advisory boards will yield the most insight.
Blurred lines
A near-universal ambition of the patient advocate is a simple one; a seat at the table. When I’ve been invited to that all-important table, it is sometimes as a professional with whatever strictures and expectations that brings. Other times it’s to share my perspective as a patient. I’ve rarely had the chance to be both at once. This conflict of identity surfaces in the sourcebook too.
It is a great testament to the existing collaboration between industry, patient organisations, charities and patient advocates that this sourcebook exists. It has the ability to make real, lasting change to the ways in which pharma interact with the patient communities they serve. But we must remember, however glib, that the person and the patient are interchangeable. I can’t give you statistics on the number of people working in industry who live with a chronic condition of some kind because personal health is a private matter, but from an anecdotal view, I suspect it is high. If I am right, that means there are a significant number of us working in the healthcare world who already have the experience and tools to tap into their inner patient.
That raises a simple question, how might you, if you sat on the other side of the table, want to be addressed, listened to, partnered with, supported and compensated? The more of us who contemplate this, the stronger chance we have of filling in any remaining blanks in patient and industry collaboration.
Elly Aylwin-Foster, strategist and copywriter.
If you’d like to learn more about how Cuttsy+Cuttsy are helping their clients focus on patient centricity, please contact us at letstalk@cuttsyandcuttsy.com.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Another year, another B!
Louise Jones, Cuttsy+Cuttsy's Sustainability Officer reflects on their latest year of carbon reporting through CDP and on achieving another B rating.
Jon Hume Joins Cuttsy+Cuttsy as New Commercial Director
Cuttsy+Cuttsy is excited to announce the appointment of Jon Hume as Commercial Director, effective 1st March 2024.
Clinical trial considerations: Why supporting HCPs matters...
When HCPs have the necessary information, they can more easily communicate it to patients using simplified language and a confident, calm tone.
Clinical trial considerations: Why diversity matters...
Diversity in clinical trials is crucial for understanding diseases and developing new treatments. Here's why diversity matters...
Clinical trial considerations: Why digital matters...
Digital technology in healthcare is rapidly evolving. In this blog we delve into how digital solutions can help improve patient experience within clinical trials.
Clinical trials explained: Why imagery matters...
Recruiting patients for clinical trials is one of pharma's greatest challenges. Imagery is a great way to connect with people on an emotional level and forms a big part the...
Clinical trials explained: Why health literacy matters...
Clinical trial recruitment can be a challenge. By applying the principles of health literacy to all materials, we can support people to make an informed choice about whether to take...
Clinical trials explained: Why iconography matters...
Icons serve as a useful form of alternative communication. We spend a lot of time developing icons for healthcare communications. Find out how we use iconography to elevate clinical trial...
Cuttsy+Cuttsy appoints Harriet Karia as Managing Director
Cuttsy+Cuttsy is pleased to announce the appointment of Harriet Karia as its first Managing Director.
Using generative AI in healthcare comms - our promise to our clients
It’s safe to say one of the hottest topics of 2023 has been ChatGPT and the launch of other Generative AI-driven applications. So, we’re sharing our promises, so that when...